{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:10:58Z","timestamp":1783581058714,"version":"3.55.0"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Antimelanoma differentiation antigen 5-dermatomyositis (MDA5-DM) is a complex and serious systemic autoimmune disease that primarily affects the skin and lungs. In this review, we aimed to provide new insights into the clinical features, pathogenesis, and practical management approach for this disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Although lung lesions are prominent in most patients with MDA5-DM, they are now recognized as heterogeneous diseases. Peripheral blood lymphocyte count can serve as a simple and reliable laboratory parameter for categorizing MDA5-DM into three subgroups: mild, medium, and severe. Recent studies have implicated viral infection, genetic factors, autoimmunity against MDA5, multiple immune cells, and interferons as significant contributors to MDA5-DM pathogenesis. In addition to traditional treatments with glucocorticoids and immunosuppressants, many new approaches, including new biologics and targeted agents, have been explored. Additionally, infection is a common complication of MDA5-DM, and prophylaxis or treatment of the infection is as important as treating the primary disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Knowledge of clinical characteristics and pathogenesis of MDA5-DM has grown in recent years. Although many new therapeutic approaches have been explored, further studies are required to confirm their efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001034","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T10:02:04Z","timestamp":1721037724000},"page":"459-465","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Antimelanoma differentiation antigen 5-positive dermatomyositis: an update"],"prefix":"10.1097","volume":"36","author":[{"given":"Xin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"105136","DOI":"10.1016\/j.ebiom.2024.105136","article-title":"MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C)","volume":"104","author":"David","year":"2024","journal-title":"EBioMedicine"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"937667","DOI":"10.3389\/fimmu.2022.937667","article-title":"Anti-MDA5 antibody linking COVID-19, type I interferon, and autoimmunity: a case report and systematic literature review","volume":"13","author":"Tonutti","year":"2022","journal-title":"Front Immunol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/joim.13607","article-title":"Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis","volume":"293","author":"Jin","year":"2023","journal-title":"J Intern Med"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.nmd.2022.05.011","article-title":"256(th) ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8\u201310 October","volume":"32","author":"Damoiseaux","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"e003150","DOI":"10.1136\/rmdopen-2023-003150","article-title":"Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease","volume":"9","author":"Chen","year":"2023","journal-title":"RMD Open"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/BOR.0000000000000908","article-title":"Anti-MDA5 dermatomyositis: an update from bench to bedside","volume":"34","author":"Fuzzi","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"152352","DOI":"10.1016\/j.semarthrit.2023.152352","article-title":"Spontaneous pneumomediastinum in anti-MDA5-positive dermatomyositis: prevalence, risk factors, and prognosis","volume":"65","author":"Jin","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"304","DOI":"10.55563\/clinexprheumatol\/df2oc3","article-title":"Antimelanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses","volume":"40","author":"Yang","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.42308","article-title":"Identification of three different phenotypes in anti\u2013melanoma differentiation\u2013associated gene 5 antibody\u2013positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease","volume":"75","author":"Xu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"e001202","DOI":"10.1136\/rmdopen-2020-001202","article-title":"Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease","volume":"6","author":"Nishina","year":"2020","journal-title":"RMD Open"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"102788","DOI":"10.1016\/j.autrev.2021.102788","article-title":"The seasonality of Dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger","volume":"20","author":"Toquet","year":"2021","journal-title":"Autoimmun Rev"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3899\/jrheum.220259","article-title":"Antimelanoma differentiation-associated gene 5 antibody-positive interstitial lung disease after vaccination with COVID-19 mRNA vaccines","volume":"49","author":"Kitajima","year":"2022","journal-title":"J Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/acr2.11423","article-title":"Presence and implications of anti-angiotensin converting enzyme-2 immunoglobulin m antibodies in anti-melanoma-differentiation-associated 5 dermatomyositis","volume":"4","author":"Mecoli","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","article-title":"Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups","volume":"78","author":"Rothwell","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","article-title":"Brief report: Association of HLA-DRB1\u22170101\/\u22170405 with susceptibility to antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3899\/jrheum.170165","article-title":"HLA-DRB1 alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis","volume":"44","author":"Chen","year":"2017","journal-title":"J Rheumatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/tan.13171","article-title":"Genetic association of HLA-DRB1 multiple polymorphisms with dermatomyositis in Chinese population","volume":"90","author":"Lin","year":"2017","journal-title":"HLA"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/annrheumdis-2017-212149","article-title":"Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis","volume":"77","author":"Kochi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1093\/rheumatology\/kead006","article-title":"WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease","volume":"62","author":"Guo","year":"2023","journal-title":"Rheumatology"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2023-225035","article-title":"Characterised intron retention profiles in muscle tissue of idiopathic inflammatory myopathy subtypes","volume":"83","author":"Xiao","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"e134189","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cei\/uxad059","article-title":"The role of neutrophil extracellular traps and proinflammatory damage-associated molecular patterns in idiopathic inflammatory myopathies","volume":"213","author":"Ma","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/cei\/uxad104","article-title":"Neutrophil extracellular traps are involved in the occurrence of interstitial lung disease in a murine experimental autoimmune myositis model","volume":"215","author":"Bai","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"743704","DOI":"10.3389\/fimmu.2021.743704","article-title":"RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-\u03b1","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/rheumatology\/kead400","article-title":"Autoantibodies against the melanoma differentiation\u2013associated protein 5 in patients with dermatomyositis target the helicase domains","volume":"63","author":"Van Gompel","year":"2024","journal-title":"Rheumatology"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12931-023-02362-0","article-title":"Enhanced immune complex formation in the lungs of patients with dermatomyositis","volume":"24","author":"Zaizen","year":"2023","journal-title":"Respir Res"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"e2313070121","DOI":"10.1073\/pnas.2313070121","article-title":"Autoimmunity against melanoma differentiation\u2013associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice","volume":"121","author":"Ichimura","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/annrheumdis-2020-218661","article-title":"Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1\u03b3 can result in experimental myositis","volume":"80","author":"Okiyama","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","article-title":"Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis","volume":"32","author":"Chen","year":"2012","journal-title":"Rheumatol Int"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"117321","DOI":"10.1016\/j.cca.2023.117321","article-title":"Decrease in cell counts and alteration of phenotype characterize peripheral NK cells of patients with anti-MDA5-positive dermatomyositis","volume":"543","author":"Lin","year":"2023","journal-title":"Clin Chim Acta"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s10067-019-04457-w","article-title":"Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody","volume":"38","author":"Jiang","year":"2019","journal-title":"Clin Rheumatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/rheumatology\/key341","article-title":"CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"R39-20250526","first-page":"237","article-title":"Expansion of exhausted CD8+ T cells associates with increased pulmonary fungal infection risk in antimelanoma differentiation associated gene 5 dermatomyositis","volume":"42","author":"Xu","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"103420","DOI":"10.1016\/j.autrev.2023.103420","article-title":"IFN-\u03b3: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies","volume":"22","author":"Thuner","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.42785","article-title":"Prognostic role of interferon-\u03bb3 in anti\u2013melanoma differentiation\u2013associated gene 5\u2013positive dermatomyositis-associated interstitial lung disease","volume":"76","author":"Fukada","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti\u2013melanoma differentiation\u2013associated gene 5\u2013positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3899\/jrheum.2023-0371","article-title":"Long-term prognosis of antimelanoma differentiation\u2013associated gene 5\u2013positive dermatomyositis with interstitial lung disease","volume":"50","author":"Sasai","year":"2023","journal-title":"J Rheumatol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"883699","DOI":"10.3389\/fmed.2022.883699","article-title":"Mortality risk stratification using cluster analysis in patients with myositis-associated interstitial lung disease receiving initial triple-combination therapy","volume":"9","author":"Gono","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"e14999","DOI":"10.1111\/1756-185X.14999","article-title":"Aggressive multicombination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease","volume":"27","author":"Hata","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-024-05551-2","article-title":"Baricitinib for antimelanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease","volume":"44","author":"Harada","year":"2024","journal-title":"Rheumatol Int"},{"key":"R48-20250526","article-title":"Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction","volume":"10","author":"Oba","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/25785826.2024.2336687","article-title":"Successful treatment with tofacitinib for antimelanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature","volume":"47","author":"Yamazaki","year":"2024","journal-title":"Immunol Med"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ard-2023-223919","article-title":"Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients","volume":"82","author":"Xue","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-020-05530-5","article-title":"Antimelanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3899\/jrheum.2023-0544","article-title":"Clinical improvement in early onset interstitial lung disease using rituximab in children with antimelanoma differentiation-associated gene 5-positive juvenile dermatomyositis","volume":"51","author":"Peskin","year":"2024","journal-title":"J Rheumatol"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"102941","DOI":"10.1016\/j.jaut.2022.102941","article-title":"Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease","volume":"133","author":"Bay","year":"2022","journal-title":"J Autoimmun"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/1744-9987.14106","article-title":"Effectiveness and safety of plasma exchange for anti-MDA5 antibody\u2013positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease refractory to intensive immune suppression therapy: a case series","volume":"28","author":"Watanabe","year":"2024","journal-title":"Ther Apher Dial"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2169\/internalmedicine.1410-22","article-title":"Early initiation of plasma exchange therapy for anti-MDA5(+)dermatomyositis with refractory rapidly progressive interstitial lung disease","volume":"63","author":"Sasaki","year":"2024","journal-title":"Intern Med"},{"key":"R57-20250526","first-page":"291","article-title":"Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe antimelanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis","volume":"41","author":"Shirai","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","article-title":"Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis","volume":"163","author":"Holzer","year":"2023","journal-title":"Chest"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"e003238","DOI":"10.1136\/rmdopen-2023-003238","article-title":"Rescue combination treatment of anti-MDA5-associated ARDS with daratumumab","volume":"9","author":"Ostendorf","year":"2023","journal-title":"RMD Open"},{"key":"R60-20250526","first-page":"460","article-title":"Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab","volume":"42","author":"Chua","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00296-019-04398-2","article-title":"Clinical spectrum and therapeutics in Canadian patients with antimelanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review","volume":"39","author":"Huang","year":"2019","journal-title":"Rheumatol Int"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s10067-022-06422-6","article-title":"Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: report of two cases and review of the literature","volume":"42","author":"Lian","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"e21943","DOI":"10.1097\/MD.0000000000021943","article-title":"Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report","volume":"99","author":"Ishikawa","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"e236431","DOI":"10.1136\/bcr-2020-236431","article-title":"MDA-5 dermatomyositis complicated by interstitial lung disease and cutaneous ulcers: successful treatment with corticosteroids, mycophenolate mofetil and intravenous immunoglobulin","volume":"13","author":"Stager","year":"2020","journal-title":"BMJ Case Rep"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"e253960","DOI":"10.1136\/bcr-2022-253960","article-title":"Treatment of myopathy and cutaneous ulcers in anti-MDA5-positive dermatomyositis with triple therapy","volume":"17","author":"Peringeth","year":"2024","journal-title":"BMJ Case Rep"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10067-022-06401-x","article-title":"Cardiac involvement in anti-MDA5 dermatomyositis: a case-based review","volume":"42","author":"Quintero-Gonz\u00e1lez","year":"2022","journal-title":"Clin Rheumatol"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1093\/rheumatology\/kead008","article-title":"Successful outcome under multiple therapy in two cases of anti-MDA5 dermatomyositis with severe cardiomyopathy and interstitial lung disease","volume":"62","author":"Roeser","year":"2023","journal-title":"Rheumatology"},{"key":"R74-20250526","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1346-8138.15274","article-title":"Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis","volume":"47","author":"Matsuda","year":"2020","journal-title":"J Dermatol"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-021-02606-8","article-title":"High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center","volume":"23","author":"Huang","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1093\/rheumatology\/kead063","article-title":"High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis","volume":"62","author":"Chen","year":"2023","journal-title":"Rheumatology"},{"key":"R77-20250526","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1093\/rheumatology\/kead034","article-title":"Compounded sulfamethoxazole improved the prognosis of dermatomyositis patients positive with antimelanoma differentiation-associated gene 5","volume":"62","author":"Liu","year":"2023","journal-title":"Rheumatology"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/JIR.S460702","article-title":"Prevalence, risk factors, and mortality of invasive pulmonary Aspergillosis in patients with Anti-MDA5+ dermatomyositis: a retrospective study in China","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflamm Res"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:18:42Z","timestamp":1748294322000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001034","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}